ToolGen has appointed Yoo Jong-sang as the new CEO, the company announced on the 27th.
The newly appointed CEO, Yoo, is an expert in antibody pharmaceuticals and cell and gene therapies, having obtained a Ph.D. in molecular biology and genetics from Pohang University of Science and Technology POSTECH. He previously worked at the Samsung Advanced Institute of Technology (SAIT) as a researcher, served as the chief at Samsung Bioepis, was a research fellow at the Institute for Basic Science, and was the head of strategic planning at Theragen Etex.
While working as the head of the Bio Center at Daewoong Group, he oversaw research and development strategies for biopharmaceuticals and cell and gene therapy projects. He later co-founded Apicell Therapeutics with a British pharmaceutical company and worked as the chief executive officer and chief strategy officer.
ToolGen is set to officially appoint Yoo Jong-sang as CEO after its regular shareholders' meeting and board of directors meeting on the 28th.
Hah Chang-hyup has been appointed as the chief financial officer of ToolGen. Hah, a finance and accounting expert, graduated from Seoul National University with a degree in business administration and is a certified public accountant. He also holds a master's degree in pharmacy from Yonsei University, which enhances his expertise in the pharmaceutical field. He has been responsible for accounting consulting, fund management, investment attraction, and financial management at Samil, Eugene Asset Management, and Bukwang Pharmaceutical.
Lee Byung-hwa, CEO of ToolGen, said, "With the newly recruited leaders Yoo Jong-sang and Hah Chang-hyup, we will build a new leadership for ToolGen and hope to grow into a global corporation leading the gene-editing field."